医学
质子疗法
肺癌
核医学
放射治疗
肺炎
阶段(地层学)
肺
放射科
内科学
生物
古生物学
作者
Nathan Y. Yu,T.A. DeWees,Molly M. Voss,William G. Breen,Jennifer S. Chiang,Julia Ding,T.B. Daniels,Dawn Owen,Kenneth R. Olivier,Yolanda I. Garces,Sean S. Park,Jann N. Sarkaria,Ping Yang,P. Savvides,Vinicius Ernani,Wei Liu,Steven E. Schild,Kenneth W. Merrell,Terence T. Sio
标识
DOI:10.1016/j.cllc.2022.07.017
摘要
Abstract
Introduction
Intensity-modulated proton therapy (IMPT) has the potential to reduce radiation dose to normal organs when compared to intensity-modulated radiation therapy (IMRT). We hypothesized that IMPT is associated with a reduced rate of cardiopulmonary toxicities in patients with Stage III NSCLC when compared with IMRT. Methods
We analyzed 163 consecutively treated patients with biopsy-proven, stage III NSCLC who received IMPT (n = 35, 21%) or IMRT (n = 128, 79%). Patient, tumor, and treatment characteristics were analyzed. Overall survival (OS), freedom-from distant metastasis (FFDM), freedom-from locoregional relapse (FFLR), and cardiopulmonary toxicities (CTCAE v5.0) were calculated using the Kaplan-Meier estimate. Univariate cox regressions were conducted for the final model. Results
Median follow-up of surviving patients was 25.5 (range, 4.6-58.1) months. Median RT dose was 60 (range, 45-72) Gy [RBE]. OS, FFDM, and FFLR were not different based on RT modality. IMPT provided significant dosimetric pulmonary and cardiac sparing when compared to IMRT. IMPT was associated with a reduced rate of grade more than or equal to 3 pneumonitis (HR 0.25, P = .04) and grade more than or equal to 3 cardiac events (HR 0.33, P = .08). Pre-treatment predicted diffusing capacity for carbon monoxide less than equal to 57% (HR 2.8, P = .04) and forced expiratory volume in the first second less than equal to 61% (HR 3.1, P = .03) were associated with an increased rate of grade more than or equal to 3 pneumonitis. Conclusions
IMPT is associated with a reduced risk of clinically significant pneumonitis and cardiac events when compared with IMRT without compromising tumor control in stage III NSCLC. IMPT may provide a safer treatment option, particularly for high-risk patients with poor pretreatment pulmonary function.
科研通智能强力驱动
Strongly Powered by AbleSci AI